Vivek Subbiah: WCLC24 Presidential symposium update

Vivek Subbiah shared a post on X:

“Sunday Morning WCLC24 Presidential symposium update ivonescimab v. pembrolizumab PFS HR 0.51, median PFS 11.1 months vs. 5.8 months. Detailed data show Summit therapy beat Merck blockbuster Keytruda in late-stage lung cancer trial via STAT news, Adam Feuerstein.

Nice to follow this virtually getting ready for ESMO24 .”

Source: Vivek Subbiah/X

Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research and former Associate Professor in the Department of Investigational Cancer Therapeutics at the MD Anderson Cancer He focuses on translational cancer research and the design and implementation of early-phase biomarker-driven clinical trials. His work specifically targets antibody-drug conjugates, radiopharmaceuticals, immunoconjugates, and basket trials.